As of September 1st, Inrebic® is reimbursed in Belgium for the treatment of splenomegaly or disease-related symptoms in adult patients with primary myelofibrosis, myelofibrosis secondary to polycythaemia vera, or secondary to essential thrombocythaemia who were previously treated with ruxolitinib and are no longer eligible for treatment with ruxolitinib.
Reimbursement conditions are mentioned on the INAMI/RIZIV website. The efficacy and safety of Inrebic® have been demonstrated in JAKARTA-2 clinical trial in which 98% of the patients achieved a spleen volume reduction (SVR), 31% reached a SVR≥35% at the end of cycle 6 (EOC6) and 27% achieved ≥50% symptom reduction at EOC6 (Harrison et al., 2020).
Top
